Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;16(4):503-7.
doi: 10.4103/2230-8210.97994.

Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan

Mir Iftikhar Bashir  1 , Md Faruque Pathan, Syed Abbas Raza, Jamal Ahmad, A K Azad Khan, Osama Ishtiaq, Rakesh K Sahay, Aisha Sheikh, Abdul Hamid Zargar
Affiliations

Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan

Mir Iftikhar Bashir et al. Indian J Endocrinol Metab. 2012 Jul.

Abstract

It is obligatory for all adult Muslims to observe fast during the holy month of Ramadan, but sick individuals including those with diabetes mellitus are exempted from the duty of fasting. Specific medical advice must be provided to individual patients concerning the potential risks they must accept if they decide to fast. Any alteration in medications deemed necessary to provide an effective and safe antidiabetic regimen should be instituted well before the start of Ramadan. Diet-controlled patients and those well controlled on insulin sensitizers have low risk of hypoglycemia and may safely fast with some modification in the timing of the doses. Newer generation sulfonylureas (gliclazide MR and glimepiride) have reasonable safety profile during Ramadan fasting and are economical options for a large number of diabetics worldwide, especially in the developing countries; older, long acting sulfonylureas like glibenclamide and chlorpropamide should be avoided during fasting. Oral DPP-IV inhibitors are important substitutes to sulfonylureas for patients with diabetes mellitus during fasting owing to their glucose-dependent mechanism of action, efficacy, and tolerability. This group of drugs causes a moderate A1c reduction, are weight neutral, and have a very low risk of hypoglycemia. Short-acting insulin secretagogues are an option in the subset of fasting diabetic patients who have predominantly post-prandial hyperglycemia.

Keywords: Gliptins; Ramadan fasting; hypoglycemia; insulin sensitizers; sulfonylureas.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Salti I, Bénard E, Detournay B, Bianchi- Biscay M, Le Brigand C, Voinet C, et al. EPIDIAR study group. A populationbased study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: Results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27:2306–11. - PubMed
    1. Al-Arouj M, Assaad-Khalil S, Buse J, Fahdil I, Fahmy M, Hafez S, et al. Recommendations for management of Diabetes during Ramadan. Update 2010. Diabetes Care. 2010;33:1895–902. - PMC - PubMed
    1. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386–99. - PubMed
    1. Vasan S, Thomas N, Bharani, Ameen M, Abraham S, Job V, et al. A double-blind, randomized, multicenter study evaluating the effects of pioglitazone in fasting Muslim subjects during Ramadan. Int J Diabetes Dev Ctries. 2006;26:70–6.
    1. Al-Arouj M, Bouguerra R, Buse J, Hafez S, Hassanein M, Ibrahim MA, et al. American Diabetes Association recommendations for management of diabetes during Ramadan. Diabetes Care. 2005;28:2305–11. - PubMed